Treatment Advances and Management of ES-SCLC
Panelists discuss the current treatment landscape of ES-SCLC, review recent clinical trials, and how they prepare their sites for tarlatamab administration, patient monitoring and management of adverse events
EP. 1: ES-SCLC vs. LS-SCLC: Critical Differences in Disease Burden and Patient Prognosis
April 24th 2025Panelists discuss how distinguishing between limited-stage and extensive-stage small cell lung cancer is essential for guiding treatment strategies, accurately staging disease, and setting appropriate expectations for prognosis and therapeutic outcomes.
EP. 2: Current Treatment Paradigm: Evolution of First-Line Therapy for ES-SCLC
April 24th 2025Panelists discuss how the addition of immune checkpoint inhibitors to first-line chemotherapy has transformed the treatment of extensive-stage small cell lung cancer, improving survival while highlighting ongoing challenges in managing relapse and the need for continued research into novel therapies.
